Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Jesse Veenstra; Jie Wang; Kathleen McKinnon-Maksimowicz; Tingting Liu; Bobby Zuniga; Iltefat Hamzavi; Li Zhou; Qing-Sheng Mi

doi:10.1136/annrheumdis-2021-220736

Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Ann Rheum Dis. 2021 Oct;80(10):e160. doi: 10.1136/annrheumdis-2021-220736. Epub 2021 Jun 10.

Authors

Jesse Veenstra^#^{1

2

3}, Jie Wang^#^{1

2

3}, Kathleen McKinnon-Maksimowicz⁴, Tingting Liu^{1

2

3}, Bobby Zuniga^{1

2

3}, Iltefat Hamzavi¹, Li Zhou^{1

2

3}, Qing-Sheng Mi^{5

2

3}

Affiliations

¹ Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA.
² Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA.
³ Immunology Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA.
⁴ Division of Rheumatology, Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA.
⁵ Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA qmi1@hfhs.org.

^# Contributed equally.

No abstract available

Keywords: COVID-19; autoimmune diseases; immune system diseases; vaccination.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines*
Cohort Studies
Humans
Immunogenicity, Vaccine
Immunosuppression Therapy*
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger

Publication types

MeSH terms

Substances

Grants and funding